The assay worked for tumor-associated peptides with an intermediate (Melan-A) and low (NLGNX and PTP) T-cell precursor frequency within the naïve T-cell repertoire, although the excellent MHC-binding affinity of the two latter glioma peptides (200–300 fold higher than for Melan-A26-35L, according to the NetMHC4.0 algorithm) might also have contributed to optimal T-cell priming. The gene discussed is MLANA; the disease is glioma.